Miruvor
Sign up
The short answer

What studies of EECP (enhanced external counterpulsation, Flow Therapy) found

8papers on EECP (enhanced external counterpulsation, Flow Therapy)
1 (few people)person in 1 study testing EECP (enhanced external counterpulsation, Flow Therapy) alone
0randomised trials, the strongest kind of study

At a glance, by condition

Long COVID: C Might help, very uncertain

Based on the strongest evidence, studies with no comparison group (very low certainty): 3 findings, all C.

3 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: EECP (enhanced external counterpulsation, Flow Therapy) might help some people with long COVID, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects and all 8 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. EECP (enhanced external counterpulsation, Flow Therapy) · Long COVID is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Symptoms

Breathlessness1 study · 1 (few people) person received EECP (enhanced external counterpulsation, Flow Therapy) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · three days per week for five weeks · one-hour sessions, three times per week (few people)

Breathlessness improved.

The evidence is very uncertain about the effect of EECP (enhanced external counterpulsation, Flow Therapy) on breathlessness in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Enhanced External Counterpulsation as a Novel Treatment for Post-acute COVID-19 Sequelae. (2021)

    People in the study
    1 in the study
    Dose
    one-hour sessions, three times per week
    Outcome
    shortness of breath
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Cognition (brain fog)1 study · 1 (few people) person received EECP (enhanced external counterpulsation, Flow Therapy) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · three days per week for five weeks · one-hour sessions, three times per week (few people)

Cognition (brain fog) improved.

The evidence is very uncertain about the effect of EECP (enhanced external counterpulsation, Flow Therapy) on cognition (brain fog) in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Enhanced External Counterpulsation as a Novel Treatment for Post-acute COVID-19 Sequelae. (2021)

    People in the study
    1 in the study
    Dose
    one-hour sessions, three times per week
    Outcome
    “brain fog”
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Overall symptoms1 study · 1 (few people) person received EECP (enhanced external counterpulsation, Flow Therapy) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · three days per week for five weeks · one-hour sessions, three times per week (few people)

Overall symptoms improved.

The evidence is very uncertain about the effect of EECP (enhanced external counterpulsation, Flow Therapy) on overall symptoms in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Enhanced External Counterpulsation as a Novel Treatment for Post-acute COVID-19 Sequelae. (2021)

    People in the study
    1 in the study
    Dose
    one-hour sessions, three times per week
    Outcome
    returning to pre-COVID health and fitness
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Side effects

No study of this treatment alone reported side effects we could read.

All papers

  1. Enhanced External Counterpulsation Improves Cognitive Function of Persons With Long COVID.2024 · no comparison group · 80 with outcome data
    Summary

    This retrospective evaluation aimed to determine the effects of enhanced external counterpulsation (EECP) in patients with long COVID and objectively assessed cognitive impairment. Eighty long COVID patients referred for EECP with cognitive sequela, who had completed an objective digital assessment before and after therapy, were included for analyses: 38 cognitive impairment vs. 42 no cognitive impairment. Patients had either cognitive impairment or no cognitive impairment at baseline. The study assessed changes in composite score using multifactor analysis of variance; multiple linear and logistic regression analyses were also conducted. The paper reports that 'There was significant improvement in composite score post EECP in those with objective cognitive impairment at baseline.' It also states 'There were no notable documented safety concerns.' Treatment duration, dose, schedule and route were not reported, and no between-group result is reported. The authors note 'a lack of a negative control group is a limitation of this study.' No information on funding or conflicts was reported.

  2. Enhanced External Counterpulsation as a Novel Treatment for Post-acute COVID-19 Sequelae.2021 · case report · 1 in the study
    Summary

    This case report describes a 38-year-old woman with post-acute sequelae of SARS-CoV-2 infection (PASC) after acute COVID-19 in October 2020; she had an at-home recovery. She was given enhanced external counterpulsation (EECP) in one-hour sessions, three times per week, as a non-standard regimen of three days per week for five weeks. There was no comparison group. The reported measures were patient-reported symptoms: “brain fog,” shortness of breath, and returning to pre-COVID health and fitness. After one week, her “brain fog” had improved, with shortness of breath improving after 1.5 weeks. The patient reported returning to pre-COVID health and fitness after approximately five weeks of EECP treatment. Side effects and withdrawals were not reported. The authors state that more data are needed to further validate these findings.

  3. Management of Long-COVID Postural Orthostatic Tachycardia Syndrome With Enhanced External Counterpulsation.2021 · case report · 1 in the study
    Summary

    This case report described one 57-year-old female with long-COVID-19-associated POTS after COVID-19 in December 2020; she was referred to an enhanced external counterpulsation (EECP) treatment center. The abstract reports 15, one-hour sessions over three weeks, while the case presentation reports a modified abbreviated regimen of 15, one-hour treatment sessions (three times a week for five weeks). There was no comparison group. At completion of 15 sessions, the patient reported less “brain fog” and ability to perform activities of daily living; her PROMIS Fatigue score decreased from moderate (score = 15) to mild (score = 12), a reduction of three points; six-minute walk test distance improved from 910 ft at baseline to 995 ft post-EECP, an increase of 85 feet; DASI improved from 0 to 15.45, over 15 points; and CCS class decreased by one. Seattle Angina Questionnaire and Rose Dyspnea Scale scores remained relatively unchanged. After nine, one-hour treatments over three weeks, she reported improvement in chest pain, SOB/DOE, and fatigue, with symptoms less frequent and less severe and of shorter duration. Blood pressure was 95/67 mmHg pretreatment and 105/57 mmHg posttreatment. Harms and withdrawals were not reported. The authors state the report is the first case and warrants further trials.

  4. The Effectiveness of Non-Pharmacological Interventions in Treating Adolescents and Young Adults with Neuropsychiatric Symptoms of Long COVID: A Systematic Review and Meta-Analysis.2026 · systematic review
    Summary

    This systematic review and meta-analysis examined non-pharmacological interventions for neuropsychiatric symptoms of long COVID in adolescents and young adults aged 13–25 years. The review included seven studies; the recorded sample sizes were 17, 16, 208, 124, 22, 239, and 36 participants. Interventions included forest bathing, TTM, a neuropsychological rehabilitation program, a multidisciplinary post-COVID rehabilitation program, micro-choice based concentrated group rehabilitation, and EECP. Durations varied, and the review reported that most studies lacked a comparison group. Outcomes included mental health, anxiety, depression, fatigue, QoL, cognitive function, headaches, and insomnia. In the meta-analysis, the pooled mental health result was statistically significant (SMD 0.64, 95% CI 0.0012 to 1.2692, p<0.0497). Pooled results for fatigue (SMD 1.74, 95% CI −0.9416 to 4.4262, p=0.1307), QoL (SMD −1.34, 95% CI −5.2620 to 2.5784, p=0.2787), and cognitive function (SMD 1.05, 95% CI −2.1961 to 4.2934, p=0.2989) were not statistically significant. Individual studies reported improvements in several outcomes; Chokpaisam et al reported no statistically significant change in emotional well-being (78.35 ± 17.44 vs 81.18 ± 17.99, p=0.336), and Kvale et al reported no statistically significant difference in anxiety and depression (27.3% vs 38.2%, p=0.210). No harms or withdrawals were recorded. The authors stated limitations including cohort designs without comparison groups, no age-based subgroup analyses, small sample sizes, and heterogeneity.

  5. Clinical effectiveness of rehabilitation in ambulatory care for patients with persisting symptoms after COVID-19: a systematic review.2023 · systematic review
    Summary

    This systematic review asked whether rehabilitation treatments applicable in ambulatory care help adults with persisting symptoms after COVID-19. Searches on 9 May 2022 identified 45,479 records, and 38 studies comprising 2,790 participants were included. Interventions included physical training, breathing exercises, nutritional supplements, olfactory training, multidisciplinary treatment, and other treatments such as hyperbaric oxygen therapy; treatment duration was not reported. Comparisons varied, including low- versus high-intensity training in 76 men and advanced versus classical olfactory training in 80 patients. Outcomes included fatigue, dyspnoea, pain, physical capacity, pulmonary function, sensory function, quality of life, return to activities, functional capacity, and adverse events. Physical training and breathing exercises may reduce fatigue, dyspnoea, and chest pain and may improve physical capacity and quality of life, with very weak evidence; improvement was not demonstrated for muscle pain or return to work. Low-intensity training increased handgrip strength and quality of life compared with high-intensity training. Advanced olfactory training was not superior to classical training. Hyperbaric oxygen therapy can have beneficial effects on fatigue in one cohort of 10 patients. Side effects with olfactory training occurred in 18 out of 80 participants. Reported adverse events included hospitalisations, dizziness, symptom exacerbation such as fatigue, headache in one participant, and post-exertional malaise after exercise.

  6. Return-to-work for people living with long COVID: A scoping review of interventions and recommendations.2025 · review
    Summary

    This scoping review asked which interventions may support return-to-work (RTW) or work ability in people living with Long COVID. The authors searched five electronic databases and grey literature up to January 3, 2025, and included 19 intervention studies and 12 clinical practice guidelines; study designs included cohort, quasi-experimental, observational, interventional, RCT and case-report designs. No comparison group was analysed. Interventions included multimodal and interdisciplinary work-focused rehabilitation, psychoeducation, pacing, breathing strategies, cognitive rehabilitation and workplace RTW planning, plus enhanced external counterpulsation, CICT and pulsed electromagnetic field therapy. Reported durations included a 3-day concentrated program, a 36-hour CICT intervention, and follow-up at six months and one-year. Findings varied: some studies reported improvement in workability, sick leave, fatigue, functional status, cognitive function or RTW; others reported no RTW improvement (Derksen et al. 2023), no significant overall RTW enhancement with physical conditioning (Hasenoehrl et al. 2023), 72% still unable to RTW after rehabilitation (Muller et al. 2023), and a 2% RTW improvement with a psychotherapy-based inpatient program (Kupferschmitt et al. 2023). The review states that graded exercise is contraindicated for people with PEM and that interventions ignoring PEM risk worsening fatigue.

  7. The effects of enhanced external counter-pulsation on post-acute sequelae of COVID-19: A narrative review.2025 · review
    Summary

    This narrative review examines mechanisms linking PASC to anxiety and the possible role of enhanced external counter-pulsation (EECP). It enrolled no patients; findings come from studies it cites. In cited work, EECP was given to 51 patients with long COVID-19, to a retrospective analysis of 80 long-COVID-19 patients (38 with cognitive impairments and 42 without), to a single 38-year-old female with PASC, and to 50 patients with refractory angina pectoris; one cited study of 50 patients reported improvement after 1 course. Cited outcomes included cognitive performance, fatigue, brain fog, cardiac function classification, anxiety scale scores, daily anginal episodes (fell from 2.7 to 0.9), and quality of life/exercise capacity at 12 months. A cited randomized controlled study of 240 CAD patients reported higher VEGF1/VEGFR2 and improved endothelial function versus control after 1-year follow-up; a controlled study in coronary slow flow reported increased FMD and lowered CRP versus control. Casey et al. reported 35 h of EECP lowered TNF-α and MCP-1 by 29 and 20%. Side effects and withdrawals are not reported. The review states further research is needed because few clinical studies have been conducted.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime